Long term results of a phase II trial of Induction Chemotherapy with Uracil-Ftegafur (UFT), Vinorelbine and Cisplatin (UFTVP) followed by Radiotherapy concomitant with UFT and Carboplatin (RT/UFTJ) in Non-Resectable Locally Advanced (Stage IV-B) Squamous Cell Head and Neck Carcinoma and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia

Rivera, Fernando; Vega-Villegas, M. E.; López‐Brea, Marta; García‐Castaño, Almudena; Juan, Ana De; Ramos, Francisco Javier; Collado, Antonio; Galdós, Piedad; Rubio, Antonio; Valle, Adolfo del; Rama, J; Mayorga, Marta; Sanz-Ortiz, Jaime

doi:10.1007/s12094-007-0008-5

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several Phase I and II trials have evaluated its efficacy and tolerance in HNSCC, as induction treatment or in combination with radiotherapy (concurrent or sequential) (35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46). However, no Phase III trial has compared UFT with another chemotherapy protocol.…”

Section: Discussionmentioning

confidence: 99%

Concomitant Chemoradiotherapy Using Carboplatin, Tegafur-Uracil and Leucovorin for Stage III and IV Head-and-Neck Cancer: Results of GORTEC Phase II Study

Fesneau¹,

Pointreau²,

Chapet³

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Concomitant Chemoradiotherapy Using Carboplatin, Tegafur-Uracil and Leucovorin for Stage III and IV Head-and-Neck Cancer: Results of GORTEC Phase II Study

Fesneau¹,

Pointreau²,

Chapet³

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Vinorelbine has been studied for its clinical efficiency in treating HNSCC (10,11,39,40); however it has been used in late/recurrent stages only (12)(13)(14)(15)(16)(17)(18)41). To date, no biomarkers have been suggested as possible companion indicators for vinorelbine treatment in head and neck cancer.…”

Section: % CI --------------------------------------------------------mentioning

confidence: 99%

Overexpression of HURP mRNA in head and neck carcinoma and association with in�vitro response to vinorelbine

et al. 2020

View full text Add to dashboard Cite

HURP gene encodes the hepatoma upregulated protein (HURP), a microtubule associated protein regulating mitotic spindle dynamics, which promotes chromosomal congression and alignment during mitosis, with a potential role in tumorigenesis. In the present study, HURP mRNA expression was investigated by reverse transcription-quantitative PCR in oropharyngeal squamous cell carcinoma (OPSCC). Primary OPSCC tumors from 107 patients and 48 adjacent normal tissues, as well as 12 respiratory tract cancer cell lines (9 head and neck squamous cell carcinoma, 2 lung cancer and 1 normal bronchial) were utilised in the present study. mRNA expression levels of HURP were higher in malignant OPSCC tissues compared with in normal mucosa (P<1x10-5) and significantly associated with sex and smoking status (P<0.0001). Vinorelbine in vitro toxicity at half-maximal inhibitory concentration (IC 50) was measured in the 11 cancer cell lines using an MTT assay. Sensitivity to vinorelbine was significantly correlated with HURP expression (r=0.636; P=0.035). The data indicated that HURP overexpression is frequent in OPSCC tissues and associated with smoking. The correlation between HURP mRNA expression and vinorelbine in vitro response suggests that HURP is a potential modulator of vinorelbine response; therefore, it should be explored for its possible predictive value for the efficiency of vinorelbine treatment in this type of cancer.

show abstract

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation

et al. 2013

View full text Add to dashboard Cite

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

show abstract

Abstract: Although toxicity is important, this approach has interesting activity and deserves further investigation.

Cited by 3 publications

References 21 publications

Concomitant Chemoradiotherapy Using Carboplatin, Tegafur-Uracil and Leucovorin for Stage III and IV Head-and-Neck Cancer: Results of GORTEC Phase II Study

Concomitant Chemoradiotherapy Using Carboplatin, Tegafur-Uracil and Leucovorin for Stage III and IV Head-and-Neck Cancer: Results of GORTEC Phase II Study

Overexpression of HURP mRNA in head and neck carcinoma and association with in�vitro response to vinorelbine

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation

Contact Info

Product

Resources

About